The Prevnar franchise is PFE’s biggest seller not related to COVID. In the adult segment of the market, Prevnar-20 has achieved a 97% market share with MRK’s Vaxneuvance a very distant #2 (#msg-169520866, #msg-166441188).
The pediatric segment of the pneumococcal-vaccine market figures to be more competitive since MRK’s Vaxneuvance has a head start from its FDA approval in Jun 2022 (#msg-169208458).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.